作者: N. Papanas , E. Maltezos
DOI: 10.4137/CMT.S1085
关键词: Insulin 、 Internal medicine 、 Glucose uptake 、 Metabolic disorder 、 Heart failure 、 Type 2 diabetes 、 Biomedical engineering 、 Medicine 、 Diabetes mellitus 、 Insulin resistance 、 Metformin
摘要: Metformin is now the most widely prescribed oral hypoglycemic agent. This review outlines its use in treatment of type 2 diabetes. The main mechanisms action include reduction appetite and intestinal carbohydrate absorption, inhibition hepatic gluconeogenesis, increased glucose uptake by peripheral tissues. has been established as drug choice for first-line According to broadly accepted guidelines, it should be administered early at diagnosis this metabolic disorder, alongside diet exercise. agent may also safely efficaciously combined with all other agents, enabling a useful additive effect. Additionally, conjunction insulin. combination aims offset insulin resistance, reduce requirements minimize weight gain. Of greater importance, metformin consistently shown have favorable effect on cardiovascular risk factors improve outcomes. Interestingly, efficacy accompanied excellent safety: caution only needed avoid patients obvious contraindications (mainly chronic renal failure, congestive heart obstructive pulmonary disease, liver disease). Moreover, cost-effectiveness established. Generally, an both specialized setting primary health care.